Corneal inflammation after miniature keratoprosthesis implantation.
暂无分享,去创建一个
[1] Beatriz Munoz,et al. Long-term outcomes of boston type 1 keratoprosthesis implantation: a retrospective multicenter cohort. , 2014, Ophthalmology.
[2] C. Dohlman. Alkali burn to the eye: Protection using TNF-a inhibition , 2014 .
[3] A. Shukla,et al. UV Cross-linking of Donor Corneas Confers Resistance to Keratolysis , 2014, Cornea.
[4] H. Lee,et al. Intravenous Infusion of Mesenchymal Stem/Stromal Cells Decreased CCR7+ Antigen Presenting Cells in Mice with Corneal Allotransplantation , 2014, Current eye research.
[5] Jin A. Choi,et al. Long-term outcomes of penetrating keratoplasty in keratoconus: analysis of the factors associated with final visual acuities. , 2014, International journal of ophthalmology.
[6] R. Dana,et al. A novel murine model for keratoprosthesis. , 2014, Investigative ophthalmology & visual science.
[7] Ti Wang,et al. Photochemical activation increases the porcine corneal stiffness and resistance to collagenase digestion. , 2014, Experimental eye research.
[8] R. Dana,et al. Alkali Burn to the Eye: Protection Using TNF-&agr; Inhibition , 2014, Cornea.
[9] Lucy Q. Shen,et al. Glaucoma Progression and Role of Glaucoma Surgery in Patients With Boston Keratoprosthesis , 2014, Cornea.
[10] A. Shukla,et al. Wound Anatomy After Type 1 Boston KPro Using Oversized Back Plates , 2013, Cornea.
[11] H. Lee,et al. Analysis of macrophage phenotype in rejected corneal allografts. , 2013, Investigative ophthalmology & visual science.
[12] M. Claesson,et al. Clinical Outcome of Repeat Penetrating Keratoplasty , 2013, Cornea.
[13] Michael W. Belin,et al. Retention of the Boston keratoprosthesis type 1: multicenter study results. , 2013, Ophthalmology.
[14] K. Lathrop,et al. Azithromycin Treatment Increases Survival of High-Risk Corneal Allotransplants , 2013, Cornea.
[15] S. Schwartz,et al. POSTOPERATIVE POSTERIOR SEGMENT COMPLICATIONS IN EYES TREATED WITH THE BOSTON TYPE I KERATOPROSTHESIS , 2013, Retina.
[16] B. Seitz,et al. Morphological and Immunohistochemical Changes After Corneal Cross-Linking , 2013, Cornea.
[17] K. Miyata,et al. [Long-term outcomes of Boston keratoprosthesis]. , 2013, Nippon Ganka Gakkai zasshi.
[18] A. Djalilian,et al. Outcomes of Boston Keratoprosthesis Implantation for Failed Keratoplasty After Keratolimbal Allograft , 2012, Cornea.
[19] R. Dana,et al. Gamma-irradiation reduces the allogenicity of donor corneas. , 2012, Investigative ophthalmology & visual science.
[20] F. Yu,et al. International results with the Boston type I keratoprosthesis. , 2012, Ophthalmology.
[21] J. Stein,et al. Glaucoma Associated With Boston Type I Keratoprosthesis , 2012, Cornea.
[22] T. Neuhann,et al. [Results with the Boston keratoprosthesis]. , 2012, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.
[23] T. Neuhann,et al. Ergebnisse nach Boston-Keratoprothese , 2012, Der Ophthalmologe.
[24] E. Sarchielli,et al. Effects of riboflavin/UVA corneal cross‐linking on keratocytes and collagen fibres in human cornea , 2010, Clinical & experimental ophthalmology.
[25] K. Tsubota,et al. Retinal phototoxicity in a novel murine model of intraocular lens implantation , 2009, Molecular vision.
[26] Z. Yalniz-Akkaya,et al. Repeat Penetrating Keratoplasty: Indications and Prognosis, 1995–2005 , 2009, European journal of ophthalmology.
[27] D. Coster,et al. Risk Factors for Human Corneal Graft Failure Within the Australian Corneal Graft Registry , 2008, Transplantation.
[28] R. Mohan,et al. Topical interleukin-1 receptor antagonist inhibits inflammatory cell infiltration into the cornea. , 2008, Experimental eye research.
[29] J. Scott,et al. Therapeutic keratoplasty for advanced suppurative keratitis. , 2007, American journal of ophthalmology.
[30] R. Dana. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). , 2007, Transactions of the American Ophthalmological Society.
[31] G. Lang. [Cross linking]. , 2007, Klinische Monatsblatter fur Augenheilkunde.
[32] James V Aquavella,et al. Introduction to the use of the Boston keratoprosthesis , 2006 .
[33] H. Al‐Mezaine,et al. Repeat penetrating keratoplasty: indications, graft survival, and visual outcome , 2006, British Journal of Ophthalmology.
[34] R. Tandon,et al. Indications and outcome of repeat penetrating keratoplasty in India , 2005, BMC ophthalmology.
[35] J. Naor,et al. Outcomes of Repeat Penetrating Keratoplasty and Risk Factors for Graft Failure , 2003, Cornea.
[36] U. Rehany,et al. The profile of repeated corneal transplantation. , 2001, Ophthalmology.
[37] D. Larkin,et al. Cytokine and chemokine expression kinetics after corneal transplantation. , 2000, Transplantation.
[38] N. P. Patel,et al. Indications for and outcomes of repeat penetrating keratoplasty, 1989-1995. , 2000, Ophthalmology.
[39] E. Cohen,et al. Indications for and outcomes of repeat penetrating keratoplasty. , 1990, American journal of ophthalmology.
[40] T. Luger,et al. Corneal epithelial cell--derived thymocyte-activating factor (CETAF). , 1982, Investigative ophthalmology & visual science.